Get updates delivered to you daily. Free and customizable.
targetedonc.com
Second-Line Therapy for ESA-Refractory, Transfusion Dependent Lower-Risk MDS: Imetelstat
By Mikkael Sekeres, MD,
2 days agoBy Mikkael Sekeres, MD,
2 days agoRead in NewsBreak
Comments / 0
Add a Comment
YOU MAY ALSO LIKE
targetedonc.com2 days ago
Melbourne, FL1 hour ago
Pompano Beach, FL14 days ago
Florida State12 days ago
mcknightsseniorliving.com25 days ago
rheumnow.com11 days ago
Chicago, IL26 days ago
curetoday.com3 days ago
oncnursingnews.com3 days ago
myfourandmore.com19 days ago
Colorado State10 days ago
Tennessee State17 days ago
Ohio State2 days ago
physiciansweekly.com2 days ago
hcplive.com3 days ago
targetedonc.com1 day ago
odtmag.com1 day ago
Get updates delivered to you daily. Free and customizable.
It’s essential to note our commitment to transparency:
Our Terms of Use acknowledge that our services may not always be error-free, and our Community Standards emphasize our discretion in enforcing policies. As a platform hosting over 100,000 pieces of content published daily, we cannot pre-vet content, but we strive to foster a dynamic environment for free expression and robust discourse through safety guardrails of human and AI moderation.
Comments / 0